CURE Pharmaceutical (OTCQB: CURR), based in Oxnard, CA, is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage forms and delivery systems. CURR has an FDA- and DEA- registered, GMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform. CUREform™ includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods™ a novel chewable delivery system.
CURR names Canopy Rivers Chairman John K. Bell, FCA, FCPA, ICD.D to its board of directors.
Bell brings more than 40 years of experience to the company, most recently serving as chairman of the Canopy Rivers board of directors and former chairman of Canopy Growth’s board of directors
CURR offers combined technologies that provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURR partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets. The CURR company mission is to improve people’s lives by redefining how medicines are delivered and experienced.
CURR Products Fall Into Two Categories: Nutraceuticals (dietary supplements) and Pharmaceutical Medicines
CUREfilm® Sleep is a daily dietary supplement that delivers a unique blend of five active ingredients with the CUREfilm® platform to promote healthy sleep patterns. This product is launched in U.S. markets.
CUREfilm® D is a high-potency dietary supplement that provides 50,000 IU of Vitamin D3 delivered with the CUREfilm® platform.
CUREfilm™ Hemp delivers hemp extracts via the CUREfilm® dosage form. This product is launched in U.S. markets.
CUREfilm® β-Caryophyllene is a dietary supplement that contains 30mg of β-Caryophyllene, a powerful terpene known for its anti-inflammatory and analgesic properties.
CUREfilm® Blue contains 50mg of Sildenafil delivered with the CUREfilm® platform.
CUREfilm® Canna delivers synthetic and plant-derived cannabinoids in an oral thin film for pharmaceutical indications.
CURR Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery
On February 5thCURR announced that it had signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products. The agreement grants ReLeaf Europe exclusive access to the CURR encapsulation technology for certain oral and topical cannabis products in the Netherlands, the world’s first medical cannabis market. ReLeaf Europe products will be the first to use the CUREinside™ quality mark to bolster consumer confidence. Europe is one of the world’s largest medical cannabis markets due to various governments’ approval for medicinal purposes.
ReLeaf Europe is one of the few pharmacy providers of pharmaceutical-grade medicinal cannabis oils in Europe and an ideal partner for the CURR first step into the European market because of its commitment to establishing clinical evidence and following EU GMP and GDP standards. Through this agreement, CURR will roll out its powered by CURE strategy that includes exclusive licensing relationships to build global market share.
Major Earnings Potential in the Emerging Medicinal Cannabis Industry
The global legal marijuana market is likely to reach over USD 66.3 billion by the end of 2025 and CURR is poised to be a big part of it with it’s drug delivery patents.
CURRhas signed a licensing and collaboration agreement with Vanguard Scientific Systems, Inc.
Vanguard is a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including the MIDAS XII, a next-generation GMP compliant supercritical CO2 extraction technology, as well as industrially scaled CO2 facility solutions. The license gives Vanguard the right to practice CURE’s patented cannabis extraction methods, providing customer confidence in choosing Vanguard’s portfolio of extraction manufacturers
The industry is poised to grow to $2.1 billion in 2020, a 700% increase from 2016. CURR is strategically positioned with multiple high value assets and extremely well-placed marketing partners to optimize the company’s earnings potential in the growing fields of key drug supply and delivery solutions, including the multi-billion-dollar CBD marketplace.
For more information on CURE Pharmaceutical(OTCQB: CURR) visit: https://medium.com/@smallcap/cure-pharmaceutical-otcqb-curr-is-a-vertically-integrated-drug-delivery-and-development-company-7d618bfa298e
Company Name: Cure Pharmaceuticals, Inc.
Contact Person: Media Relations
Email: Send Email
Phone: (805) 824-0410
Address:1620 Beacon Place
State: CA 93033
Country: United States